Abstract: Methods and systems are provided for sample preparation techniques and sequencing of macromolecular constituents of cells and other biological materials.

Abstract: A wicking apparatus includes a composite condenser membrane comprising a substrate layer, a vapor inlet end, a liquid discharge end, a plurality of cavities disposed in the substrate layer fluidly coupling the vapor inlet end to the liquid discharge end, and a nanoporous filler material disposed within the plurality of cavities. The nanoporous filler material has a first plurality of open pores with a maximum diameter in the range of 0.2 to 200 nanometers. The first end of the liquid conduit is fluidly coupled to the liquid discharge end of the composite condenser membrane. The wicking apparatus further includes a wick composite evaporator membrane comprising a substrate layer, a liquid inlet end, a vapor discharge end, a plurality of cavities disposed in the substrate layer fluidly coupling the liquid inlet end to the second end of the liquid conduit, and a nanoporous filler material disposed within the plurality of cavities.

Abstract: A wicking apparatus includes a composite condenser membrane comprising a substrate layer, a vapor inlet end, a liquid discharge end, a plurality of cavities disposed in the substrate layer fluidly coupling the vapor inlet end to the liquid discharge end, and a nanoporous filler material disposed within the plurality of cavities. The nanoporous filler material has a first plurality of open pores with a maximum diameter in the range of 0.2 to 200 nanometers. The first end of the liquid conduit is fluidly coupled to the liquid discharge end of the composite condenser membrane. The wicking apparatus further includes a wick composite evaporator membrane comprising a substrate layer, a liquid inlet end, a vapor discharge end, a plurality of cavities disposed in the substrate layer fluidly coupling the liquid inlet end to the second end of the liquid conduit, and a nanoporous filler material disposed within the plurality of cavities.

Abstract: The present invention provides, inter alia, novel, liposome-based formulations for enhanced ophthalmic drug delivery. Such ophthalmic drug formulations are useful for treating ocular inflammation stemming from, for example, iritis, conjunctivitis, seasonal allergic conjunctivitis, acute and chronic endophthalmitis, anterior uveitis, uveitis associated with systemic diseases, posterior segment uveitis, chorioretinitis, pars planitis, masquerade syndromes including ocular lymphoma, pemphigoid, scleritis, keratitis, severe ocular allergy, corneal abrasion, or blood-aqueous barrier disruption, and for treating post-operative ocular inflammation, resulting from, for example, photorefractive keratectomy, cataract removal surgery, intraocular lens implantation or radial keratotomy.